Eli Lilly (LLY) Stock Price, Quote, News & History | Benzinga

Eli Lilly and Co (LLY) — Q1 FY26 Earnings Call Live coverage with Benzinga. Q1 FY26 Results EPS: $8.55 (est. $6.85) — inline Revenue: $19.80B (est. $17.78B) — inline Reported: 2026-04-30 Recent Quarters Q4 FY25 (2026-02-04): EPS $7.54 vs est $6.96 · Rev $19.30B vs est $17.91B Q3 FY25 (2025-10-30): EPS $7.02 vs est $5.96 · Rev $17.60B vs est $16.05B Q2 FY25 (2025-08-07): EPS $6.31 vs est $5.60 · Rev $15.56B vs est $14.70B Q1 FY25 (2025-05-01): EPS $3.34 vs est $3.02 · Rev $12.73B vs est $12.66B About Eli Lilly and Co Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. https://www.lilly.com · Indianapolis, IN, USA · 50,000 employees Follow Benzinga X: https://x.com/Benzinga Facebook: https://www.facebook.com/Benzinga/ Instagram: https://www.instagram.com/benzinga/ ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #earnings #LLY #stocks #benzinga